Krystal Biotech, Inc.
Krystal Biotech, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 1, 2026, a projected date rather than a confirmed one. There are 7 upcoming events on record.
Krystal Biotech, Inc. generates cash from operations, so a burn-based runway figure does not apply.
Across 5 concluded trials, 60% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 1, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 15, 2026 | A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease | Trial Milestone | EARLY_Phase 1 |
| December 15, 2026 | A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa | Trial Milestone | Phase 3 |
| December 15, 2026 | A Study Assessing KB407 for the Treatment of Cystic Fibrosis | Trial Milestone | Phase 1 |
| December 15, 2026 | A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis | Trial Milestone | Phase 1/Phase 2 |
| February 15, 2027 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Trial Milestone | Phase 1/Phase 2 |
| July 15, 2027 | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Trial Milestone | Phase 1/Phase 2 |
Track KRYS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open KRYS in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.